- Research Article
- 10.1016/j.cmet.2026.01.015
16-h fasting optimizes cancer immunotherapy in mice and humans.
- May 05, 2026
- Cell metabolism
- Sheng Chen + 21 more +21
Publications from 2021 to 2026
Showing 10 of 220 papers
16-h fasting optimizes cancer immunotherapy in mice and humans.
Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma.
Cisplatin (CDDP) resistance represents an urgent clinical challenge. Identifying CDDP-resistant lung adenocarcinoma (LUAD) patients responsive to immunotherapy through novel biomarkers is critical for improving survival outcomes. CDDP resistance genes were identified from RNA-seq data of A549 cells in the GEO database. RNA sequencing, genetic mutations, and clinical data of LUAD patients were obtained from TCGA. Patients were split into training and validation cohorts. A prognostic model was developed using LASSO and multivariate Cox regression, with validation in both cohorts. Tumor mutation burden (TMB), immune activity, and functional enrichment analyses (GO, KEGG) were performed to explore the link between lncRNA and CDDP resistance. Twenty-three CDDP resistance-associated genes were identified from GEO. Co-expression analysis revealed 507 CDDP resistance-linked lncRNAs. Cox regression analysis identified three CDDP resistance-related lncRNAs: ARAP1-AS2, LINC01843, and LINC02198. RT-PCR verified these lncRNAs and representative mRNAs (KIF21B, B3GNT3, PLXNA2). Patients stratified by median risk score showed significantly worse overall survival (OS) and higher mortality in high-risk groups. Univariate/multivariate Cox analyses confirmed the risk score as an independent prognostic factor. A nomogram predicted LUAD survival outcomes. Low-risk patients exhibited significantly lower TMB than high-risk counterparts, with low-risk/high-TMB patients showing optimal OS. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm revealed significant differences in immune dysfunction, CD8+ T cells, cancer-associated fibroblasts (CAF), and tumor-associated macrophages (TAM-M2) between risk groups. These three CDDP resistance-associated lncRNAs including ARAP1-AS2, LINC01843, and LINC02198, serve as reliable prognostic biomarkers for LUAD. The findings provide insights for immunotherapeutic strategies and personalized treatment development.
Read moreAnti-inflammatory effects of 1,8-cineol via NF-κB/COX-2 pathway in BEAS-2B cells and alleviates bronchoconstriction and airway hyperreactivity in ovalbumin sensitized mice.
Asthma is a chronic inflammatory airway disease characterized by airway remodeling and hyperresponsiveness, driven in part by TGF-β1-induced epithelial-mesenchymal transition (EMT). The natural compound 1,8-cineol, derived from Eucalyptus globulus, has shown anti-inflammatory potential. This study aimed to investigate its protective effects against EMT and airway inflammation via the NF-κB/COX-2 pathway. In vivo, ovalbumin-sensitized BALB/c mice were treated with 1,8-cineol (50 mg/kg) to evaluate airway resistance, lung compliance, and inflammatory markers (IgE, IL-4, IL-13, IL-17). Histopathological changes were assessed via H&E and PAS staining. In vitro, TGF-β1-stimulated BEAS-2B cells were treated with 1,8-cineol to analyze EMT markers (α-SMA, E-cadherin, N-cadherin), migration capacity, and NF-κB/COX-2 signaling using RT-qPCR, Western blotting, and transwell assays. 1,8-cineol significantly attenuated airway hyperresponsiveness and reduced EMT markers (α-SMA, N-cadherin) in OVA-sensitized mice, while improving lung compliance. In BEAS-2B cells, it suppressed TGF-β1-induced EMT and migration without cytotoxicity. Mechanistically, 1,8-cineol downregulated NF-κB phosphorylation and COX-2 expression. OVA challenge elevated serum IgE and BALF cytokines (IL-4, IL-13, IL-17), which were mitigated by 1,8-cineol. 1,8-cineol inhibits TGF-β1-driven EMT and airway inflammation by modulating the NF-κB/COX-2 pathway, highlighting its therapeutic potential for asthma.
Read moreRBM15B promotes hepatocellular carcinoma progression via IGF2BP1-mediated ITSN2 mRNA stabilization.
N6-methyladenosine (m6A) is a chemical modification of adenosine in RNA that plays a crucial role in the regulation of gene expression. As the most abundant form of RNA chemical methylation, m6A is aberrantly expressed in hepatocellular carcinoma (HCC), where it affects multiple biological processes including targeted RNA splicing, transport, degradation, stabilization, and translation. RBM15B (RNA-binding motif protein 15B), is a gene that encodes a protein involved in RNA processing and regulation. RBM15B is a member of the RNA-binding motif (RBM) protein family, which plays diverse roles in post-transcriptional gene regulation. RBM15B is proven to be involved in mRNA processing, including pre-mRNA splicing, mRNA transport, and mRNA stability. It may also participate in other RNA-related processes such as mRNA translation and RNA decay. We investigated the phenotypes of RBM15B in HCC using the TCGA database, in-vitro, and in vivo assays. m6A dot blot was used to assess RNA methylation levels and Merip-seq/RNA-seq were employed to explore the biological effects and potential mechanisms of RBM15B in HCC. We hypothesized that RBM15B may regulate ITSN2 expression in HCC. To test this, RNA immunoprecipitation (RIP) followed by qRT-PCR was applied for the identification and characterization of target ITSN2 mRNA that interacted with RNA binding protein IGF2BP1, which may mediate the effects of RBM15B. To further elucidate the functional relationship between RBM15B and ITSN2, we performed rescue assays of cell proliferation and migration to determine whether RBM15B over-expression is able to restore the loss of function induced by ITSN2 knockdown to an extent. High levels of RBM15B were verified by both TCGA data and our cohort. High levels of RBM15B predicted a poor prognosis. RBM15B promotes HCC propagation and invasion in vitro and in vivo. RBM15B regulates the m6A of intersectin2 (ITSN2) mRNA via insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1)-facilitated stabilization of ITSN2 mRNA. ITSN2 depletion rescued the tumor-promoting phenotype induced by RBM15B overexpression. In summary, RBM15B-regulated m6A in ITSN2 mRNA facilitates HCC progression via IGF2BP1-guided stabilization of ITSN2 mRNA. Our study illustrates the importance of the RBM15B-IGF2BP1-ITSN2 regulatory axis based on m6A activity and provides new insights into epi-transcriptomic maladjustments of initiation and metastasis in HCC.
Read moreQuercetin targets IL6/JAK1/STAT3/MMP9 signaling to attenuate breast cancer progression in diabetic comorbidity: A multi-omics and experimental study.
Stimuli-responsive logical gate biosensor based on integrated DNAzyme probe for the discrimination of cancer cells.
Effects of vasoactive intestinal peptide on neuroexcitability of female-specific subpopulation of myelinated Ah-type neurons isolated from trigeminal ganglia of adult female rats.
Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.
NPM1-mutated acute myeloid leukemia (AML) is a distinct entity with specific biological and clinicopathological features. Prognosis varies depending on the associated mutations and clinical characteristics. This study evaluated the prognostic factors of NPM1-mutated AML in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). We enrolled 139 patients with NPM1-mutated AML who underwent allo-HSCT. The median age at allo-HSCT was 47 years with a median follow-up of 1,134 days. The 3-year cumulative incidence of relapse (CIR), leukemia-free survival (LFS), and overall survival (OS) rates were 15.1%, 78.4%, and 78.0%, respectively. FLT3-ITD mutations showed higher CIR (22.6% vs 5.3%, P = 0.006), lower LFS (70.9% vs 88.1%, P = 0.019), and reduced OS (70.8% vs 87.5%, P = 0.036). FLT3-ITD and DTA mutations indicated adverse prognosis, while IDH1/2 mutations showed improved outcomes. Matched sibling donor (MSD) allo-HSCT patients had higher CIR and lower LFS and OS than unrelated donor (URD) or haploidentical-related donor (HRD) recipients. Pre-HSCT MRD status affected the outcomes, with MRD+ and nCR patients showing worse outcomes. Multivariable analysis identified FLT3-ITD, MSD, and pre-MRD status as significant predictors. In conclusion, FLT3-ITD and DTA mutations are associated with an adverse prognosis, whereas HRD or URD transplants may offer better outcomes than MSD allo-HSCT.
Read morePoliovirus Receptor as a Potential Target in Gastric Signet-Ring Cell Carcinoma for Antibody-Drug Conjugate Development.
Gastric signet-ring cell carcinoma (GSRCC) is a distinct subtype of gastric cancer characterized by unique biological features, leading to low rates of early diagnosis, poor prognosis, and limited response to chemotherapy and immunotherapy. Effective targeted therapies for GSRCC remain scarce. Given these treatment challenges and the potential efficacy of antibody-drug conjugates (ADCs) in clinical settings, this study focuses on identifying novel ADCs with significant potential to improve the treatment outcomes of GSRCC. We conducted a comprehensive bioinformatics analysis of GSRCC using multi-omics data (including transcriptomics and proteomics) and identified the poliovirus receptor (PVR) as a potential therapeutic target for GSRCC. We selected deruxtecan (DXd) as an effective carrier for developing an ADC targeting GSRCC. The synthesized PVR monoclonal antibody-DXd complex (PVR-DXd) has a drug-to-antibody ratio (DAR) of 4. PVR-DXd demonstrated potent antitumor activity in a human GSRCC xenograft model, effectively eliminating tumors while sparing normal tissue, highlighting its potential as a novel and impactful targeted therapy for this aggressive subtype of gastric signet ring cell carcinoma. This preliminary study supports the further development of PVR-DXd as a candidate therapy for advanced GSRCC.
Read moreEfficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases
BACKGROUNDThe liver represents a common site of distant metastasis in patients with esophageal cancer (EC). Conventional chemotherapy (CMT) presents limited efficacy for EC, and EC patients with liver metastases typically experience a poor prognosis, highlighting an urgent need to explore novel treatment approaches. This study evaluated the overall efficacy and safety of CMT vs CMT combined with immune checkpoint inhibitors (ICIs) in the treatment of EC patients with liver metastases. Furthermore, prognostic factors influencing outcomes in this patient population were identified.AIMTo evaluate the efficacy and safety of first-line chemoimmunotherapy for EC patients with liver metastases and to analyze prognostic factors.METHODSThis retrospective study included 126 EC patients with liver metastases at Zhejiang Cancer Hospital between 2014 and 2024. Patients receiving CMT were compared with those receiving CMT + ICI. Analyzed variables included clinicopathological features, treatment history, characteristics of metastasis, systemic and local treatments, overall survival (OS), and treatment-related adverse events (TRAEs). Prognostic factors were evaluated using univariate and multivariate Cox proportional-hazards regression models. Finally, efficacy outcomes and TRAE profiles were compared between the two groups.RESULTSA significant difference in median OS was identified between the two groups (10.8 months in the CMT group vs 20.8 months in the CMT + ICI group, P = 0.004). The CMT + ICI group also demonstrated a significantly longer median progression-free survival of 11.7 months (P < 0.001). Patients receiving combination therapy exhibited significantly improved systemic objective response rate and disease control rate. Multivariate analysis identified key factors significantly influencing OS in EC patients with liver metastases: Karnofsky Performance Status score ≥ 70, receipt of local therapy for liver metastases, and the number of cycles of CMT and immunotherapy received. Furthermore, the incidence of TRAEs did not significantly differ between the CMT + ICI and CMT groups.CONCLUSIONFor EC patients with liver metastases, the combination of CMT and ICIs demonstrates significantly superior efficacy compared with CMT alone, while maintaining manageable TRAEs.
Read more